Q1 2024 Earnings Estimate for Zimmer Biomet Holdings, Inc. Issued By Zacks Research (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities researchers at Zacks Research raised their Q1 2024 earnings estimates for shares of Zimmer Biomet in a report issued on Monday, April 22nd. Zacks Research analyst U. Biswas now forecasts that the medical equipment provider will post earnings per share of $1.88 for the quarter, up from their previous forecast of $1.86. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.07 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q1 2026 earnings at $2.26 EPS.

A number of other analysts also recently commented on ZBH. StockNews.com downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. TheStreet upgraded shares of Zimmer Biomet from a “c” rating to a “b-” rating in a report on Thursday, February 8th. Canaccord Genuity Group reissued a “hold” rating and issued a $130.00 target price on shares of Zimmer Biomet in a research report on Friday, February 23rd. Evercore ISI lifted their target price on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Stock Down 1.2 %

ZBH stock opened at $119.75 on Wednesday. Zimmer Biomet has a 52 week low of $102.00 and a 52 week high of $149.25. The company has a market capitalization of $24.60 billion, a price-to-earnings ratio of 24.49, a price-to-earnings-growth ratio of 2.23 and a beta of 1.01. The firm’s 50-day moving average is $126.09 and its two-hundred day moving average is $119.46. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The company had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same period in the previous year, the firm earned $1.88 EPS. Zimmer Biomet’s revenue was up 6.3% on a year-over-year basis.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s payout ratio is 19.63%.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now directly owns 44,145 shares in the company, valued at $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.95% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

Large investors have recently bought and sold shares of the stock. OLD Point Trust & Financial Services N A acquired a new position in Zimmer Biomet during the 4th quarter valued at $26,000. Ables Iannone Moore & Associates Inc. acquired a new position in Zimmer Biomet during the 4th quarter valued at $30,000. Naples Money Management LLC acquired a new position in Zimmer Biomet during the 4th quarter valued at $35,000. Activest Wealth Management raised its stake in Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 275 shares during the last quarter. Finally, Peoples Bank KS acquired a new position in Zimmer Biomet during the 3rd quarter valued at $48,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.